S&P 500   3,205.38 (-0.66%)
DOW   26,772.64 (-0.36%)
S&P 500   3,205.38 (-0.66%)
DOW   26,772.64 (-0.36%)
S&P 500   3,205.38 (-0.66%)
DOW   26,772.64 (-0.36%)
S&P 500   3,205.38 (-0.66%)
DOW   26,772.64 (-0.36%)
Log in

NYSE:AMRXAmneal Pharmaceuticals Stock Price, Forecast & News

$4.89
-0.08 (-1.61 %)
(As of 07/16/2020 11:38 AM ET)
Add
Compare
Today's Range
$4.77
Now: $4.89
$4.97
50-Day Range
$4.36
MA: $4.73
$5.11
52-Week Range
$2.27
Now: $4.89
$5.79
Volume35,877 shs
Average Volume1.34 million shs
Market Capitalization$1.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.52
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company has operations in the United States, Switzerland, India, Ireland, the United Kingdom and internationally. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Read More
Amneal Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.76 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone908-947-3120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$1.18 per share
Book Value$1.16 per share

Profitability

Net Income$-361,920,000.00

Miscellaneous

Employees5,500
Market Cap$1.46 billion
Next Earnings Date8/6/2020 (Confirmed)
OptionableOptionable

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.

Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

How has Amneal Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMRX stock has increased by 50.5% and is now trading at $4.89. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amneal Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Amneal Pharmaceuticals.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Amneal Pharmaceuticals.

How can I listen to Amneal Pharmaceuticals' earnings call?

Amneal Pharmaceuticals will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals Inc (NYSE:AMRX) issued its quarterly earnings data on Monday, May, 11th. The company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.09 by $0.11. The firm had revenue of $498.50 million for the quarter, compared to the consensus estimate of $446.12 million. Amneal Pharmaceuticals had a negative net margin of 11.85% and a positive return on equity of 22.05%. The company's quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the business earned $0.14 EPS. View Amneal Pharmaceuticals' earnings history.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals updated its FY20 earnings guidance on Monday, May, 11th. The company provided earnings per share (EPS) guidance of $0.45-0.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.50. The company issued revenue guidance of $1.88-1.98 billion, compared to the consensus revenue estimate of $1.87 billion.

What price target have analysts set for AMRX?

10 brokers have issued 12 month price targets for Amneal Pharmaceuticals' stock. Their forecasts range from $2.50 to $7.00. On average, they expect Amneal Pharmaceuticals' stock price to reach $4.69 in the next twelve months. This suggests that the stock has a possible downside of 4.1%. View analysts' price targets for Amneal Pharmaceuticals.

Has Amneal Pharmaceuticals been receiving favorable news coverage?

News coverage about AMRX stock has trended positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amneal Pharmaceuticals earned a daily sentiment score of 2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news about Amneal Pharmaceuticals.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a drop in short interest in June. As of June 15th, there was short interest totaling 6,090,000 shares, a drop of 9.2% from the May 31st total of 6,710,000 shares. Based on an average daily trading volume, of 2,190,000 shares, the days-to-cover ratio is presently 2.8 days. Approximately 6.5% of the shares of the stock are sold short. View Amneal Pharmaceuticals' Current Options Chain.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Canopy Growth (CGC), Exelixis (EXEL), Intelsat (I), Micron Technology (MU), Nektar Therapeutics (NKTR), Teva Pharmaceutical Industries (TEVA), AbbVie (ABBV), Amarin (AMRN) and Alibaba Group (BABA).

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
  • Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
  • Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
  • Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
  • Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $4.89.

How big of a company is Amneal Pharmaceuticals?

Amneal Pharmaceuticals has a market capitalization of $1.46 billion and generates $1.63 billion in revenue each year. The company earns $-361,920,000.00 in net income (profit) each year or $0.27 on an earnings per share basis. Amneal Pharmaceuticals employs 5,500 workers across the globe.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is www.amneal.com.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.